


January 31, 2026

Technology: Etanercept is a recombinant tumor necrosis factor receptor ("TNFR")-Fc fusion protein that is indicated for the treatment of various types of arthritis, ankylosing spondylitis, and plaque psoriasis.


Etanercept Claims Challenged in IPR and Litigation*



*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints.

VENABLE LLP

Etanercept Timeline



VENABLE LLP

	Sandoz v. Amgen 3:13-cv-02904 (N.D. Cal.) Dismissed for lack of subject matter jurisdiction; Fed. Cir. 14-1693 Affirmed	Amgen v. Sandoz 2:16-cv-01118 (D.N.J.) Patents not invalid; Stipulated to infringement; Fed. Cir. 20-1037 Affirmed, Request for <i>en banc</i> rehearing denied; Supreme Court 20-1110 Certiorari denied	Amgen v. Samsung Bioepis 2:19-cv-11755 (D.N.J.) Stipulated to infringement, Permanent injunction issued	Coalition for Affordable Drugs v. Amgen IPR2015-01792 Institution denied	Cohesus v. Hoffman-La Roche IPR2017-01916 Institution denied	Cohesus v. Hoffman-La Roche IPR2017-02066 Institution denied
7,915,225		x	x			
8,063,182	x	x	x			x
8,119,605		x	x			
8,163,522	x	x	x	x	x	
8,722,631		x	x			